Published in Oncotarget on June 21, 2016
The most important questions in cancer research and clinical oncology-Question 2-5. Obesity-related cancers: more questions than answers. Chin J Cancer (2017) 1.33
Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer (2016) 0.98
Case-control study of metabolic syndrome and ovarian cancer in Chinese population. Nutr Metab (Lond) (2017) 0.75
Single nucleotide polymorphisms in CIDEC gene are associated with metabolic syndrome components risks and antihypertensive drug efficacy. Oncotarget (2017) 0.75
Influences of Realgar-Indigo naturalis, A Traditional Chinese Medicine Formula, on the Main CYP450 Activities in Rats Using a Cocktail Method. Evid Based Complement Alternat Med (2017) 0.75
Endothelial cells microparticle-associated protein disulfide isomerase promotes platelet activation in metabolic syndrome. Oncotarget (2016) 0.75
The Association between Food Group Consumption Patterns and Early Metabolic Syndrome Risk in Non-Diabetic Healthy People. Clin Nutr Res (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
Marrow stromal cells as stem cells for nonhematopoietic tissues. Science (1997) 17.06
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res (2005) 11.88
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab (2006) 10.14
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 10.11
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst (2002) 9.65
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
Obesity-induced inflammatory changes in adipose tissue. J Clin Invest (2003) 7.50
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem (2000) 6.86
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care (2004) 6.68
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50
Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr (2004) 6.31
Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell (2008) 6.26
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999) 5.27
C-reactive protein and the risk of incident colorectal cancer. JAMA (2004) 4.94
The insulin-like growth factor system and cancer. Cancer Lett (2003) 4.91
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79
The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 4.72
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol (2005) 4.37
Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene (2006) 4.05
SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science (2009) 3.72
Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem (2004) 3.54
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci (2009) 3.39
Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell (2013) 3.32
The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am (2004) 3.20
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09
The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer (1988) 3.07
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev (2000) 3.01
Prospective study of hyperglycemia and cancer risk. Diabetes Care (2007) 2.89
Leptin and cancer. J Cell Physiol (2006) 2.88
Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A (2004) 2.85
Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology (2003) 2.84
Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans (2003) 2.81
The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil (2004) 2.79
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst (1999) 2.68
The metabolic syndrome: A high-risk state for cancer? Am J Pathol (2006) 2.46
Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care (2012) 2.21
Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer (2004) 2.05
Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) (2005) 2.05
The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology (2002) 2.03
Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy (2007) 2.01
The metabolic syndrome in cancer survivors. Lancet Oncol (2010) 1.93
The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol (2005) 1.88
The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 1.78
Association of obesity and cancer risk in Canada. Am J Epidemiol (2004) 1.71
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 1.65
Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res (2013) 1.65
Plasma adiponectin and gastric cancer. Clin Cancer Res (2005) 1.62
The biology of leptin: a review. J Anim Sci (1998) 1.53
Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev (2005) 1.52
Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer (2004) 1.52
Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci (2000) 1.51
Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr (2000) 1.50
Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia (2003) 1.44
Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila) (2012) 1.44
Signaling pathways governing tumor angiogenesis. Oncology (2011) 1.42
The link between the metabolic syndrome and cancer. Int J Biol Sci (2011) 1.37
IGF-1R as an anti-cancer target--trials and tribulations. Chin J Cancer (2013) 1.31
The metabolic syndrome - an ongoing story. J Physiol Pharmacol (2009) 1.28
Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer (2001) 1.23
Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer (2013) 1.21
Obesity, insulin resistance and cancer risk. Yonsei Med J (2005) 1.20
The role of autophagy in aging: its essential part in the anti-aging mechanism of caloric restriction. Ann N Y Acad Sci (2007) 1.16
Cancer's insatiable appetite. Nat Biotechnol (2009) 1.12
Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor-dependent signaling. Mol Med (2008) 1.11
Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer (2010) 1.11
A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis (2004) 1.10
Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol (2011) 1.09
Obesity and cancer: local and systemic mechanisms. Annu Rev Med (2015) 1.09
Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling. Oncotarget (2014) 1.08
Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev (2012) 1.08
Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer (2009) 1.07
Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer (1995) 1.06
Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol (2003) 1.04
Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol (1991) 1.03
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. Horm Metab Res (2001) 1.01
Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. Biochimie (2005) 1.00
Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis (2003) 0.99
Combinatorial stem cell mobilization. Nat Biotechnol (2009) 0.96
Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer (2008) 0.96
Are there specific treatments for the metabolic syndrome? Am J Clin Nutr (2008) 0.96
Stromal estrogen receptor-α promotes tumor growth by normalizing an increased angiogenesis. Cancer Res (2012) 0.95
Hyperglycemia promotes K-Ras-induced lung tumorigenesis through BASCs amplification. PLoS One (2014) 0.79